GlassScriptPhysician profile
Travis F Wiggins
NPI 1053486126
$3,347.36
in general payments reported to CMS, 2019-2025
31 companies · $760 in 2025
The $760 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $557 · 2020: $808 · 2021: $406 · 2022: $261 · 2023: $285 · 2024: $270 · 2025: $760.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,315.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,315.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $950.23 | 2019-2025 | Linzess, Creon, Viberzi |
| Fujifilm Healthcare Americas Corporation | $658.83 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $214.98 | 2019-2025 | Entyvio |
| Boston Scientific Corporation | $210.10 | 2019-2025 | Exalt Model D, General - Hemostasis, Resolution 360 Ultra Clip |
| Madrigal Pharmaceuticals | $180.85 | 2025 | Rezdiffra |
| Pfizer INC. | $155.98 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $124.22 | 2019-2022 | |
| Amgen INC. | $109.86 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $96.30 | 2021 | |
| Janssen Biotech, INC. | $85.00 | 2020 | |
| Nestle Healthcare Nutrition INC. | $56.72 | 2021 | |
| Mallinckrodt Hospital Products INC. | $45.73 | 2023-2025 | Terlivaz |
| Gilead Sciences, INC. | $41.42 | 2019-2025 | |
| Phathom Pharmaceuticals, INC. | $40.85 | 2025 | Voquezna |
| Intercept Pharmaceuticals, INC. | $39.56 | 2019-2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $38.32 | 2021-2023 | Zeposia |
| Genzyme Corporation | $36.82 | 2024 | |
| Ucb, INC. | $32.24 | 2019 | |
| Braintree Laboratories, INC. | $31.05 | 2020-2021 | |
| Novo Nordisk INC | $26.52 | 2025 | Wegovy |
| Ferring Pharmaceuticals INC. | $24.81 | 2024 | Rebyota |
| Redhill Biopharma INC. | $22.67 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $20.77 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $20.20 | 2024 | Iqirvo |
| Organon LLC | $18.83 | 2023 | Renflexis |
| Conmed Corporation | $16.89 | 2021 | |
| Ironwood Pharmaceuticals, INC | $13.35 | 2021 | |
| Endo Pharmaceuticals INC. | $13.34 | 2019 | |
| Shionogi INC | $11.52 | 2019 | |
| Endogastric Solutions, INC | $8.34 | 2019 | |
| Romark Laboratories, Lc | $1.06 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Travis Wiggins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.